LLY

1,048

-0.68%↓

JNJ

246.78

+0.64%↑

ABBV

228.66

+0.11%↑

NVS

167.52

+1.64%↑

MRK

124.65

+0.87%↑

LLY

1,048

-0.68%↓

JNJ

246.78

+0.64%↑

ABBV

228.66

+0.11%↑

NVS

167.52

+1.64%↑

MRK

124.65

+0.87%↑

LLY

1,048

-0.68%↓

JNJ

246.78

+0.64%↑

ABBV

228.66

+0.11%↑

NVS

167.52

+1.64%↑

MRK

124.65

+0.87%↑

LLY

1,048

-0.68%↓

JNJ

246.78

+0.64%↑

ABBV

228.66

+0.11%↑

NVS

167.52

+1.64%↑

MRK

124.65

+0.87%↑

LLY

1,048

-0.68%↓

JNJ

246.78

+0.64%↑

ABBV

228.66

+0.11%↑

NVS

167.52

+1.64%↑

MRK

124.65

+0.87%↑

Начало・Списък с акции・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

43.88 3.08

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

42.32

Максимум

43.95

Ключови измерители
By Trading Economics
Приходи	-6.2M -91M
Марж на печалбата	-867.293
Служители	316
EBITDA	4M -90M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+31.57% upside

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-25M 3.2B
Предишно отваряне	40.8
Предишно затваряне	43.88

Настроения в новините

By Acuity

50%

149 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

34.81 / 38.24 Подкрепа & съпротива

Xenon Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.02.2026 г., 22:53 ч. UTC

Придобивния, сливания и поглъщания

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23.02.2026 г., 22:36 ч. UTC

Печалби

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23.02.2026 г., 22:32 ч. UTC

Печалби

Woodside Energy Fiscal Year Net Profit Falls 24%

23.02.2026 г., 23:58 ч. UTC

Пазарно говорене

Печалби

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23.02.2026 г., 23:58 ч. UTC

Пазарно говорене

Печалби

Global Energy Roundup: Market Talk

23.02.2026 г., 23:47 ч. UTC

Пазарно говорене

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23.02.2026 г., 23:43 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23.02.2026 г., 23:41 ч. UTC

Придобивния, сливания и поглъщания

Crescent Capital Partners Owns 53% of ClearView Wealth

23.02.2026 г., 23:40 ч. UTC

Придобивния, сливания и поглъщания

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23.02.2026 г., 23:40 ч. UTC

Придобивния, сливания и поглъщания

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23.02.2026 г., 23:40 ч. UTC

Пазарно говорене

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23.02.2026 г., 23:40 ч. UTC

Придобивния, сливания и поглъщания

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23.02.2026 г., 23:39 ч. UTC

Придобивния, сливания и поглъщания

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23.02.2026 г., 23:31 ч. UTC

Печалби

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23.02.2026 г., 23:31 ч. UTC

Печалби

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23.02.2026 г., 23:28 ч. UTC

Печалби

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23.02.2026 г., 23:28 ч. UTC

Печалби

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23.02.2026 г., 23:28 ч. UTC

Печалби

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23.02.2026 г., 23:27 ч. UTC

Печалби

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23.02.2026 г., 23:24 ч. UTC

Пазарно говорене

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23.02.2026 г., 22:38 ч. UTC

Придобивния, сливания и поглъщания

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23.02.2026 г., 22:31 ч. UTC

Печалби

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23.02.2026 г., 22:24 ч. UTC

Печалби

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23.02.2026 г., 22:22 ч. UTC

Печалби

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23.02.2026 г., 22:22 ч. UTC

Печалби

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23.02.2026 г., 22:22 ч. UTC

Печалби

Viva Energy FY Underlying Ebitda A$700.9 Million

23.02.2026 г., 22:22 ч. UTC

Печалби

Viva Energy Final Dividend 3.94 Australian Cents/Security

23.02.2026 г., 22:21 ч. UTC

Печалби

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23.02.2026 г., 22:21 ч. UTC

Печалби

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23.02.2026 г., 22:20 ч. UTC

Печалби

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Сравнение с други в отрасъла

Ценова промяна

Xenon Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

31.57% нагоре

12-месечна прогноза

Среден 55.56 USD 31.57%

Висок 66 USD

Нисък 44 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Xenon Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на Xenon Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

34.81 / 38.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

149 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.